Home Healthcare Medical Devices Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market

Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of MEA) Forecasts, 2026-2034

Last Updated: July 10, 2026 | Author: Jay Mehta | Format:

Middle East and Africa Cardiac Resynchronization Therapy (crt) Market Size

The Middle East and Africa Cardiac Resynchronization Therapy Market size was valued at USD 284 million in 2025 and is projected to grow from USD 306 million in 2026 to reach USD 618 million by 2034, growing at a CAGR of 8.99% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Top 3 Key Highlights

  • CRT-D dominates the market by Product. 
  • Hospitals dominate the market by End-users.
  • South Africa dominates the market by Country.
Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Size

Download Free Sample Report To learn more about this report,

Middle East and Africa Cardiac Resynchronization Therapy (crt) Market Growth Factor

Rising Awareness about Cardiac Resynchronization Therapy (crt)

Cardiac Resynchronization Therapy is a treatment that synchronizes the contractions of the left and right ventricles of the heart using electrical impulses. Patients with heart failure who have left ventricular dysfunction and a large QRS complex on their electrocardiogram (ECG) can benefit from it. Due to the efforts of medical device companies, healthcare professionals, and governmental organizations, Cardiac Resynchronization Therapy awareness is rising in the Middle East and Africa.

Restraining Factor

Complications Associated with Cardiac Resynchronization Therapy

The most frequent problem with CRT devices is an infection, which can happen at the lead or the incision site. Serious complications from infection, like sepsis and death, are possible. Another frequent problem is lead dislodgement, which can happen if the lead is not correctly fastened. Lead displacement increases the risk of infection and can result in pacing or sensing loss. The battery in CRT devices must be changed every 5-7 years. The gadget will stop working if the battery is not changed. These complications are restraints in the Middle East and Africa Cardiac Resynchronization Therapy Market.

Market Opportunity

Regulatory Support

The effectiveness and safety of medical devices, including CRT devices, are significantly influenced by regulatory authorities. Governments in the Middle East and Africa frequently collaborate closely with regulatory bodies to create strong regulatory frameworks and speed up the licensing processes for medical devices. Regulatory support enables CRT producers to efficiently introduce their goods to the market, supporting market growth. This is done by presenting a clear path for market entry.

Product Insights

The Middle East and Africa market is segmented by CRT-D and CRT-P. CRT-D dominated the market over the forecast period.

End User Insights

The Middle East and Africa market is segmented by Hospitals, Cardiac Centre. Hospitals dominated the market over the forecast period.

Regional Analysis

The Middle East and Africa market is segmented by country into South Africa, Saudi Arabia, and UAE. South Africa dominates the country market and is expected to grow at a CAGR of 7.7% during the forecast period.

The MEA cardiac resynchronization therapy market is anticipated to grow due to key companies' initiatives and growing awareness of cardiovascular events in developing economies. Additionally, the presence of regional distributors and growing efforts to increase public awareness of heart health are anticipated to support market expansion in the upcoming years. According to a study done in Africa between 2011 and 2018, the region lacked widespread access to and utilization of cardiac arrhythmia services. CRT was discovered to be used in 12% or 52% of the responding African nations. Of the 23 countries that responded, 52% reported implanting CRT-P, while 45% reported implanting CRT-D. The cost was a substantial deterrent to using CRT-P and CRT-Ds in the area. The study identified key objectives for expanding cardiac arrhythmia services across Africa: increased economic investments, human resource training, and infrastructure improvements in the healthcare sector.

List of Key and Emerging Players in Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market

Key Industry Developments

  • May 2026: BIOTRONIK entered a research and innovation partnership with Charité – Universitätsmedizin Berlin and the German Heart Center Foundation to advance digital cardiology, AI-enabled cardiac rhythm management, and connected implantable cardiac devices, including cardiac resynchronization therapy (CRT) systems. The collaboration supports future innovations adopted across global markets, including MEA.
  • April 2026: Boston Scientific received U.S. FDA approval for design updates to its RESONATE™ CRT-D family, including enhanced communication modules and hardware improvements. These upgrades strengthen the company's global CRT portfolio, including products marketed in the Middle East and Africa.
  • September 2025: BIOTRONIK launched the Amvia Sky HF-T QP CRT-P system in Canada, expanding its quadripolar cardiac resynchronization therapy portfolio with improved workflow features and patient-focused device capabilities. The launch reinforces BIOTRONIK's global CRT product offering for international markets, including MEA.
  • June 2025: Medtronic expanded educational and physician training initiatives for cardiac rhythm management technologies, including CRT implantation and remote monitoring solutions, through international clinical education programs supporting healthcare professionals in emerging markets, including the Middle East and Africa.

Report Scope

Market Metric Details & Data (20255-2034)
Market Size in 20255 USD 284 Million
Market Size in 2026 USD 306 Million
Market Size in 2034 USD 618 Million
CAGR 8.99% (2026-2034)
Base Year for Estimation 20255
Historical Data20252-20254
Forecast Period2026-2034
Study Period 2022-2034
Key Market Players Abbott, Boston Scientific Corporation, Medtronic, Lepu Medical Technology Co., Ltd., Biotronik SE & Co. Kg
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered By Product, By End User

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

How big is the Middle East and Africa cardiac resynchronization therapy market?
The Middle East and Africa cardiac resynchronization therapy market witnessed significant growth in the past and is expected to grow at a CAGR of 8.99% during the forecast period (2026-2034).
Key verticals adopting the Middle East and Africa cardiac resynchronization therapy market include: Abbott, Boston Scientific Corporation, Medtronic, Lepu Medical Technology Co., Ltd., Biotronik SE & Co. Kg, Microport Scientific Corporation , LivaNova PLC, Medico S.R.L.
Rising awareness about cardiac resynchronization therapy (crt) is the key driver for the growth of the Middle East and Africa cardiac resynchronization therapy market.
Regulatory support is one of the upcoming key trends in the Middle East and Africa cardiac resynchronization therapy market.

Author's Details


Jay Mehta

Research Analyst

Jay Mehta is a Research Analyst with over 4 years of experience in the Medical Devices industry. His expertise spans market sizing, technology assessment, and competitive analysis. Jay’s research supports manufacturers, investors, and healthcare providers in understanding device innovations, regulatory landscapes, and emerging market opportunities worldwide.

Report Details
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
custom reports
Need a Tailored Report?
80% of our existing clients ask for tailored reports.
Request Customization
Request Sample Order Report Now

We are featured on: